Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) / Sharman, J.P., Munir, T., Grosicki, S., Roeker, L.E., Burke, J.M., Chen, C.I., Grzasko, N., Follows, G., Matrai, Z., Sanna, A., Qiu, L., Feng, R., Hua, V.M., Jurczak, W., Ritgen, M., Yi, S., Bosch, F., Coombs, C.C., Bao, K., Patel, V., et al.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 1527-7755. - 43:23(2025), p. 2658. [10.1200/JCO-25-01356]
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Ghia P.
;
2025-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
